Spatial regulation of tyrosine phosphorylation is important for many aspects of cell biology. However, phosphotyrosine accounts for less than 1% of all phosphorylated substrates, and it is typically a very transient event in vivo. These factors complicate the identification of key tyrosine kinase substrates, especially in the context of their extraordinary spatial organization. Here, we describe an approach to identify tyrosine kinase substrates based on their subcellular distribution from within cells. This method uses an unnatural amino acid-modified Src homology 2 (SH2) domain that is expressed within cells and can covalently trap phosphotyrosine proteins on exposure to light. This SH2 domain-based photoprobe was targeted to cellular structures, such as the actin cytoskeleton, mitochondria, and cellular membranes, to capture tyrosine kinase substrates unique to each cellular region. We demonstrate that RhoA, one of the proteins associated with actin, can be phosphorylated on two tyrosine residues within the switch regions, suggesting that phosphorylation of these residues might modulate RhoA signaling to the actin cytoskeleton. We conclude that expression of SH2 domains within cellular compartments that are capable of covalent phototrapping can reveal the spatial organization of tyrosine kinase substrates that are likely to be important for the regulation of subcellular structures.
Spatial regulation of tyrosine phosphorylation is important for many aspects of cell biology. However, phosphotyrosine accounts for less than 1% of all phosphorylated substrates, and it is typically a very transient event in vivo. These factors complicate the identification of key tyrosine kinase substrates, especially in the context of their extraordinary spatial organization. Here, we describe an approach to identify tyrosine kinase substrates based on their subcellular distribution from within cells. This method uses an unnatural amino acid-modified Src homology 2 (SH2) domain that is expressed within cells and can covalently trap phosphotyrosine proteins on exposure to light. This SH2 domain-based photoprobe was targeted to cellular structures, such as the actin cytoskeleton, mitochondria, and cellular membranes, to capture tyrosine kinase substrates unique to each cellular region. We demonstrate that RhoA, one of the proteins associated with actin, can be phosphorylated on two tyrosine residues within the switch regions, suggesting that phosphorylation of these residues might modulate RhoA signaling to the actin cytoskeleton. We conclude that expression of SH2 domains within cellular compartments that are capable of covalent phototrapping can reveal the spatial organization of tyrosine kinase substrates that are likely to be important for the regulation of subcellular structures.
protein phosphorylation | proteomics | signal transduction O ne of the fundamental goals in cell biology is to identify and reveal the function of molecules in subcellular space and time to understand mechanisms of cell physiology. However, the analysis of lysates is often ineffective for the description of many subcellular proteomes. Fractionation by successive biochemical purification steps can be used to identify proteins enriched in distinct organelles, but these approaches likely alter the representation of low-abundance proteins normally associated with these organelles in their naive state. Furthermore, some subcellular regions are difficult to purify biochemically. Because of the difficulty in obtaining organelle structures at high levels of purity, organelle fractionation usually requires subtractive or correlation profile analysis to identify the proteins that are enriched compared with controls (1, 2) .
Reversible protein phosphorylation is a central signaling mechanism that governs important biological functions, such as migration, proliferation, differentiation, and survival. Deregulation of phosphosignaling pathways, especially tyrosine kinases, is associated with human diseases, including cancer; thus, clarifying unregulated kinase signaling pathways is one avenue toward the development of effective drug therapies and assays for these diseases (3) . One of the critical yet still unresolved issues is the identity of kinase substrates and how these substrates are functionally organized within the cell to regulate physiology. Although recent advances in MS technologies have enabled the profiling of site-specific phosphorylation on a global scale (4-7), several challenges remain. These include the heterogeneity of phosphorylation sites, the discovery of low-abundance or transient phosphoproteins associated with specific cellular organelles, and especially the identification of phosphotyrosine due to its low stoichiometry.
In vivo, phosphotyrosine can function as a ligand for docking domains. The Src homology 2 (SH2) domain is present in 111 human proteins and is the prototypic phosphotyrosine binding domain (8) (9) (10) (11) . This phosphobinding property of the SH2 domain has been used to purify tyrosine-phosphorylated proteins in vitro by affinity chromatography (12, 13) . These SH2-based affinity purifications, as well as other in vitro phosphopeptide enrichment strategies, successfully identify phosphorylated proteins, although such approaches may potentially lose low-abundance or low-stoichiometric phosphotyrosine proteins during extraction. In addition, spurious phosphorylation or dephosphorylation during the lysis or purification steps likely leads to false-positive or false-negative phosphorylation sites, as well as the loss of the spatial organization of phosphoproteome.
In this study, we have taken advantage of a modified SH2 domain to develop a unique genetically encoded strategy to capture phosphotyrosine proteins in vivo in their native context at distinct subcellular sites. Using this approach, we have identified a total of 391 proteins and 189 specifically enriched proteins from each subcellular site. We further characterized one of the actin cytoskeletal enriched proteins, RhoA, and showed that it can be phosphorylated on two tyrosine residues within the switch regions.
modifications, we chose the SH2 domain from c-Abl, based on previous work suggesting it recognizes large numbers of phosphotyrosine proteins (15) . Three amino acid positions near the phosphotyrosyl peptide binding pocket were selected based on the crystal structure of the SH2 domain of c-Abl (16) (Fig. 1B) . Each c-Abl SH2 cDNA variant containing an amber codon [SH2amb1 (R152), SH2amb2 (R175), and SH2amb3 (N177)] was cloned into the pcpBpaV4 vector (14) and transfected into FreeStyle 293 cells. This pcpBpaV4 vector allows for the simultaneous expression of the modified SH2, together with the pBpa-specific variant of Escherichia coli tyrosyl-tRNA Tyr (Eco-pBpaRS) and the Bacillus stearothermophilus suppressor tRNA Tyr . Also, pcpBpaV4 adds affinity tags to the N terminus of the cloned insert, such that the SH2 domain can be efficiently purified by tandem affinity purification (TAP). This vector also allows for the detection of expressed SH2 domains by a C-terminal V5 epitope. pBpa was added to the growth media for 3 d posttransfection, after which the cells were treated with pervanadate (PV), followed by exposure to 365-nm light. Purified samples from these lysates were immunoblotted to determine SH2 expression by amber codon suppression (Fig. 1C) . SH2amb1 expression was consistently low, yet SH2amb2 showed intense signals with high-molecular-weight (HMW) bands compared with SH2amb3, indicating covalent binding to cellular proteins. To test whether these HMW bands were photo-crosslinking-dependent, SH2amb2 was purified with and without UV light exposure (Fig. 1D) . The results showed HMW bands were UV light-dependent, indicating most of the HMW bands were endogenous proteins phototrapped by SH2amb2. The HMW band intensity increased when cells were treated with PV, indicating the phototrapping was enhanced by increasing the levels of cellular phosphotyrosine. Moreover, under the same conditions, WT SH2 domain did not cross-link to cellular proteins, confirming that pBpa was required for cross linking in situ (Fig.  S1 ). We also assessed the capacity of these three modified SH2 domains to bind a known c-Abl SH2 ligand using the peptide overlay method (Fig. 1E) . Only SH2amb2 bound to the EGF receptor (EGFR)-derived peptide (17) in a phosphodependent manner. These results suggested that the unnatural amino acid incorporated into the SH2amb2 variant did not alter the recognition specificity toward a known phosphotyrosine peptide; however, further work would be needed to demonstrate if it retained the exact binding selectivity of the WT SH2 domain. The main goal of these experiments was to exploit the SH2 domain for its phosphobinding properties rather than to identify physiological partners of c-Abl. To this end, the overlay results confirmed that the binding was phosphodependent.
Targeting Modified SH2 Domains to Subcellular Compartments. These results suggested the expression of soluble SH2amb2 (hereafter referred to as Solu-SH2) could be used to phototrap phosphotyrosine-containing proteins within cells. Next, we targeted Solu-SH2 to specific subcellular sites within the cell to bias the trapping of phosphotyrosine proteins at these locations. Three types of subcellular localization signals were fused to the N terminus of the Solu-SH2 domain to target it to F-actin, mitochondria, or cellular membranes ( Fig. 2A) . To confirm whether the localization signals effectively targeted the pBpa-containing SH2 to subcellular compartments, we coexpressed each SH2 domain variant with control vectors (Fig. 2 B-J) . Each targeted SH2 protein colocalized with control fluorescent proteins, demonstrating the pBpa SH2 variants were targeted to the desired subcellular compartment effectively, although some soluble signal was also detected. Also, we verified the presence of tyrosine-phosphorylated proteins in each subcellular structure ( Fig. 2 K-S) . At the sites where actintargeted EGFP or membrane-targeted enhanced yellow fluorescent protein (EYFP) was expressed, phosphotyrosine staining was observed ( Fig. 2 K-P) . Additionally, the mitochondria-targeted EYFP demonstrated partial overlap with phosphotyrosine staining (Fig. 2 Q-S) . Each SH2 variant was expressed in FreeStyle 293 cells and exposed to UV light, followed by TAP, and immunoblot analysis was performed to determine the photo-cross-linked proteins. Each SH2 variant displayed a unique banding pattern (Fig.  2T) , suggesting each variant captured and enriched a unique subset of phosphoproteins.
Targeted SH2 Domains Captured Unique Proteins from Subcellular
Regions. Purified fractions from each of the three distinct subcellular compartments [actin-targeted SH2 (Act-SH2), mitochondria-targeted SH2 (Mito-SH2), and membrane-targeted Sh2 (Mem-SH2)] and without a targeting sequence (Solu-SH2) were subjected to solution trypsin digest, and tandem MS was performed to identify captured proteins. To compare identified proteins between each SH2pBpa variant fraction, hierarchical clustering was performed (Fig. 3A) . Proteins uniquely enriched in each fraction (termed PI clusters) were identified, thus removing common proteins that copurified with the baits independent of A photoactivatable cross-linker, pBpa, is translationally incorporated into the SH2 domain, the site designated by an amber codon, when coexpressed with a pBpa-specific tRNA synthetase and amber suppressor tRNA. pBpa covalently cross-links with a binding protein on UV light exposure. (B) Positions of pBpa relative to the SH2 ligand binding pocket. The surface-rendered SH2 domain structure of c-Abl was used to determine the candidate residues (colored) to be replaced with pBpa. Phosphotyrosine and P + 3 binding pockets are indicated in the figure. (C) Estimation of phototrapping efficacy of three modified SH2 domains. Modified SH2 domains SH2amb1(R175amb), SH2amb2(N177amb), and SH2amb3(S187amb) were expressed in the cell and cultured in media containing pBpa, followed by UV exposure and purification by IgG beads. Precipitants were subjected to immunoblotting (IB) with anti-V5 antibody. (D) Photoactivation and tyrosine-dependent cross linking of SH2 domain. SH2amb2 was expressed in cells and subjected to UV light with or without PV treatment. Immunoblot analysis of purified samples by anti-V5 antibody reveals HMW bands are UV and PV treatment-dependent. (E) EGFR-derived peptides were synthesized onto cellulose membrane and overlaid with the pBpa-modified SH2 domain, followed by UV exposure, and were then immunoblotted with anti-GST antibody. their location. These could result from a low level of nontargeted SH2 due to overexpression of the tagged domain or from nonspecific interactions. These PI clusters included 97 proteins from Solu-SH2, 46 proteins from Act-SH2, 24 proteins from Mito-SH2, and 22 proteins from Mem-SH2 (Dataset S1). The proteins within each PI cluster were heavily enriched for the subcellular region targeted by the SH2pBpa variants. For example, Act-SH2 phototrapping identified proteins known to be regulators of or localized to actin, including RhoA, myosin VI, gelsolin, LIMA1, and IQGAP1. By comparative analysis with the PhosphoSite and Phospho.ELM databases, potentially unique phosphoproteins were identified in each enrichment fraction (Fig. S2) , indicating the targeting and phototrapping approach could capture unique potential phosphotyrosine proteins from subcellular compartments. In addition, BCAR1, which is known to interact with cAbl in an SH2-dependent manner, was captured in the soluble, actin, and mitochondria fractions (18) . Thus, consistent with our EGFR peptide overlay, these data indicate the pBpa-containing SH2 domain retains its natural binding selectivity. Importantly, in each subcellular-targeted SH2 PI cluster, the portion of the target subcellular localization predicted by gene ontology for the identified proteins was increased compared with the Solu-SH2 PI cluster (Fig. 3B) . These results further demonstrate that targeting SH2 domain to each subcellular compartment biased the phototrapping of phosphoproteins that naturally occur at that subcellular region in situ.
Identification of Potential SH2 Binding Phosphorylation Sites by
Peptide Array Overlay. It is likely that in addition to phosphorylated proteins, nonphosphorylated proteins associated with the SH2 binding proteins would be present in the purified samples. To identify the potential tyrosine-phosphorylated proteins and the sites on these proteins that could serve as the SH2 docking site, we performed peptide array analysis. Sequences surrounding tyrosine sites from a sample of the most abundant proteins (based on peptide spectral counts) that were found in each SH2 PI cluster were arrayed onto membranes as phosphotyrosine and nonphosphotyrosine peptides. These arrays were then incubated with GST c-Abl SH2 domain, and bound GST-SH2 was detected by immunoblotting. A total of 182 peptides from 25 proteins were analyzed (Dataset S2). The resulting intensity for binding at each peptide, nonphosphopeptide vs. phosphopeptide, was measured and normalized to a positive control peptide derived from EGFR. For example H-Ras harbors nine potential phosphotyrosine sites, one of which (Y157) was reported in a phosphoproteomic study to be phosphorylated (19) . Overlay analysis confirmed the Y157 could function as an SH2 binding site in addition to other potential phosphotyrosine sites, such as Y32 (Fig. 4 A and B) . Representative results from parallel antiphosphotryosine blotting and GST-SH2 overlays verified that negative binding results were not due to variability in the phosphotyrosine peptide synthesis (Fig. S3) , consistent with other studies demonstrating the highly reproducible nature of phosphotyrosine peptide array synthesis and SH2 domain overlay (20) . Of a total 182 peptides, 28 were previously identified as phosphorylated (Fig. 4B ). The SH2 overlay screening identified 10 of these peptides. Additionally, 49 previously undescribed potential SH2-binding phosphorylation sites were identified. Binding sequences identified from the peptide array were aligned to deduce the preferred c-Abl SH2 binding sequence flanking the phosphotyrosine site ( RhoA Can Be Tyrosine-Phosphorylated on Y34 and Y66. To characterize further one of the phosphoproteins identified by the spatial phototrapping strategy, RhoA, which was identified in the Act-SH2 PI cluster, we carried out a peptide array overlay analysis with the c-Abl SH2 domain and found that RhoA had two potential SH2 binding phosphorylation sites, Y34 and Y66 (Fig. 5A ). Recently one site, Y34, was identified by a large-scale phosphoproteomics study, further validating endogenous RhoA as a tyrosine kinase substrate (19) . Rho-family GTPases share a common domain structure, consisting of a GDP/GTP-binding motif (G box) and switch I and II regions, which mediate binding to regulators [GAP and guanine nucleotide exchange factor (GEF)] and downstream effectors (22, 23) . Interestingly, Y34 and Y66 were located in these switch regions, suggesting they could be important regulatory sites of RhoA (24) (Fig. 5B ). To test whether RhoA could be tyrosine-phosphorylated in cells, RhoA was expressed in HEK 293T cells, followed by immunoprecipitation, and was immunoblotted with an antiphosphotyrosine antibody ( Fig. 5C ). RhoA was tyrosine-phosphorylated, and the phosphorylation was stimulated by PV treatment. To screen for candidate tyrosine kinases involved in RhoA phosphorylation, we coexpressed RhoA with several active tyrosine kinases ( Fig.  5D and Fig. S4 ). RhoA was phosphorylated by Bcr-Abl and Src. We also confirmed earlier work suggesting endogenous RhoA could be phosphorylated (19) . Interestingly, endogenous RhoA phosphorylation was detected only when coexpressed with BcrAbl in the presence of PV, indicating the phosphorylation of RhoA may be tightly regulated by phosphatase activity (Fig. 5E ).
Solu_SH2 proteins
To map the responsible phosphorylation site in situ, mutagenesis analyses were performed (Fig. 5F ). Y34F and Y66F RhoA mutants reduced tyrosine phosphorylation levels to 50% and 20%, respectively, compared with controls when they were coexpressed with Src (Fig. 5G ). When these RhoA mutants were coexpressed with Bcr-Abl, phosphorylation levels of Y34F and Y66F RhoA mutants dramatically decreased to 32% and 17%, respectively. As expected, when Y34 and Y66 were both mutated to phenylalanine, phosphorylation was completely abolished. Together, these observations indicate that Y34 and Y66 are the two predominant phosphorylation sites, and that the Src kinase and Bcr-Abl are the two candidate kinases that may phosphorylate these sites.
Tyrosine 34 and 66 of RhoA Appear to Be Critical for Effector Binding.
Based on their location within the switch regions, one potential functional role of phosphorylation of RhoA at Y34 and Y66 could be to regulate effector binding in vivo. To investigate this possibility, the activity of RhoA vs. RhoA mutants was tested using a two-photon excitation laser scanning microscopy with fluorescence lifetime imaging (2pFLIM) assay for RhoA effector [Rho binding domain (RBD)] binding (Fig. 6A ). Fluorescence lifetime decay curves of mEGFP-RhoA were measured to calculate the binding fraction of RhoA (25, 26) . Constitutively active RhoA (RhoAQ63L) had an approximately twofold higher fraction of RBD binding compared with WT RhoA (Fig. 6B ).
To test the potential role of phosphorylation, tyrosine 34 and 66 were mutated to glutamic acid. Although acidic amino acids cannot perfectly mimic phosphotyrosine, they are the only substitutions that have successfully been used to approximate tyrosine phosphorylation in regulating protein activity (27, 28) . In contrast to active RhoA, RhoAQ63L(Y34,66E) had a dramatic decrease in RBD binding. This binding fraction was even lower than that of WT RhoA, suggesting phosphorylation at these sites could have a negative effect on RhoA activity (Fig. 6B ). To test this notion further, RhoAQ63L was coexpressed with constitutively active Src (SrcCA) or dominant negative Src (SrcDN) (Fig.  S5A) . SrcCA reduced the binding of RhoAQ63L (17.4%) compared with SrcDN (Fig. 6C) . Because the glutamine 63 to leucine mutation in the switch 2 region of GTPases both increases basal GDP/GTP exchange and inhibits intrinsic GTPase activity, the RhoAQ63L is relatively insensitive to the activity of cellular GAPs and GEFs (29) (30) (31) . Thus, the effect of Src was a likely a direct effect on the sensor. This effect was likely via Src phosphorylation of RhoA vs. the RBD domain of the sensor because control experiments demonstrated that although Src could phosphorylate RhoA, it could not phosphorylate the RBD domain (Fig. S5B) . Together, these data suggest Y34 and Y66 are critical for the ability of RhoA to interact with downstream effectors on activation and that phosphorylation at these sites would likely inhibit activation-dependent effector binding. This possibility was tested using WT RhoA vs. RhoA(Y34,66E) in a RhoA activation assay in response to EGF treatment (Fig.  6D) . RhoA(Y34,66E), WT RhoA, and dominant negative RhoA (RhoAT19N) were expressed in the cells and stimulated with EGF to induce activation (32) . As expected, WT RhoA was potently activated by EGF treatment. In contrast, RhoA(Y34,66E) was not responsive and behaved similar to RhoAT19N (Fig. 6 D and E) .
Role of Y34 and Y66 of RhoA in Effector Binding and RhoA-Induced Actin Stress Fiber Formation. These results suggested phosphorylation of RhoA at Y34 and Y66 may inhibit binding to cellular effectors. To test this possibility, GFP-tagged RhoAQ63L or its mutant, RhoAQ63L(Y34,66E), expressed in cells was immunoprecipitated to compare interacting partners (Fig. 7A) . MS-based comparative analysis of the immunoprecipitates showed that RhoA effectors involved in the regulation of the actin cytoskeleton, such as DIAPH1, DAAM1, ROCK1/2, and PKN, were detected only in the RhoAQ63L immunoprecipitations (Fig. 7B) . Also, Rhotekin, which was used as an effector binding for 2pFLIM assay, was associated with RhoAQ63L but not with RhoAQ63L (34,66E). Importantly, RhoGAP1, a GTPase activating protein for RhoA and Cdc42 (33, 34) , was associated with both RhoA mutants, suggesting that altering tyrosine 34 and 66 does not disrupt this binding. These observations indicate that Y34 and Y66 are critical for effector binding but not for GAP binding. Importantly, it also shows the mutations did not globally disrupt RhoA folding or function but did selectively impair its ability to bind effectors. To determine the role of each tyrosine with regard to effector binding, an RBD pull-down assay was performed ( Fig. 7 C and D) . Both Y34 and Y66 were critical for Rhotekin binding, suggesting phosphorylation of either site could inhibit RhoA effector functions. Based on these results, the functional consequences to RhoA-induced cellular actin reorganization were assessed (Fig. 7 E  and F) . For this assay, RhoA (wild), RhoAQ63L, and mutants of RhoAQ63L containing either phenylalanine or glutamic acid at positions Y34 and Y66 were overexpressed in serum-starved HeLa cells and the percentage of transfected cells with elevated actin stress fiber formation was quantified. As expected, RhoAQ63L strongly induced actin stress fibers in HeLa cells, almost sixfold that of WT RhoA, which weakly stimulated stress fiber formation. In contrast, the RhoAQ63L(Y34,66E) mutant completely lost the ability to induce F-actin formation, whereas RhoAQ63L(Y34,66F) retained significant activity. These data indicate the difference in ability to stimulate cellular stress fiber formation is due to the negative charge of glutamic acid compared with the structurally similar phenylalanine. Interestingly, these results almost perfectly mirror the effector binding results of Fig. 6B , which also showed the Y34,66E form of RhoA is less active than WT RhoA.
Discussion
Here, we have demonstrated the utility of unnatural amino acidbased photo-cross linking to identify transient posttranslational modifications in vivo. Importantly, we were able to use this approach in combination with a relatively low-affinity PI module, the SH2 domain, to trap and identify transient phosphorylation events that occur at low stoichiometry. We also show this approach can be extended to interrogate phosphorylation events within distinct subcellular sites. This method should be applicable to other PI modules and opens up new avenues for exploring the organization of posttranslational modifications in cellular space. For the initial testing of this approach, we focused on the SH2 domain. SH2 domains are particularly well suited as cellular phosphotyrosine probes in that they protect these sites from rapid dephosphorylation in vivo. However, the intrinsic low binding affinity has limited their utility for purification of their cellular ligands. This limitation was overcome by the translational incorporation of the photo-cross-linkable unnatural amino acid pBpa within proximity of the ligand binding site. The evolutionary expansion of the SH2 domain to over 100 different functional variants in humans infers it is a highly robust structural scaffold capable maintaining phosphotyrosine binding in the face of mutational pressure. We exploited this property to expand the physiochemical repertoire of this domain with the incorporation of the unnatural phenylalanine analog. Because pBpa is translationally incorporated in vivo, this also presented the opportunity to add subcellular tags to the recombinant protein to direct the photo-cross-linking events to defined cellular sites. The advantage of this approach is that it allows the biochemical probing of subcellular sites in their native state without the need for extensive subcellular fractionation. Furthermore, it may allow for the interrogation of cellular sites not previously amenable to biochemical purification. For the initial testing of this approach, we sampled the actin cytoskeleton, mitochondria, and cellular membranes using the c-Abl SH2 domain. Our primary goal was not to identify physiological partners of c-Abl, per se; rather, we used this domain because previous studies had suggested it could sample a large number of phosphorylated proteins when overexpressed (15) . Indeed, in each case, we were significantly able to enrich the photo-cross-linking reaction toward proteins known to exist in each of the targeted sites within cells and to be phosphorylated. In the case of the mitochondria, the SH2 domain was targeted to the intramitochondrial space, where Src family kinases have previously been localized (35) . Approximately 40% of the proteins identified in the mitochondrial targeting experiments have previously been identified as phosphotyrosine substrates (Fig. S2) , further confirming this cellular site can be regulated by tyrosine kinases. Additionally, many of proteins identified are likely be phosphorylated at the cellular sites the SH2 was targeted to. For example, membranetargeted SH2 identified the multipass membrane protein ATPA1A, a Na + /K + exchange pump whose activity is regulated by phosphorylation of tyrosine residue 10 (36). Indeed, this site was also identified in the peptide array as the best binding site for the Abl SH2 domain (Dataset S2). Thus, this method can be used to probe defined subcellular spaces, even within organelles in living cells.
In this study, we also attempted to identify phosphotyrosine proteins associated with the actin cytoskeleton directly. This was important, given the known effects of tyrosine kinases on important actin-driven processes, such as adhesion and migration. Our analysis identified several important regulators of actin as potential phosphotyrosine proteins, including the small GTPase RhoA. Importantly, both recombinant RhoA and endogenous RhoA were tyrosine-phosphorylated; however, interestingly, the phosphorylation was only apparent on PV treatment to inhibit phosphatase activity. These results highlight that although RhoA may be a tyrosine kinase substrate, its phosphorylation is likely to be tightly regulated in vivo or that a small fraction of total cellular RhoA is phosphorylated. Often, low stoichiometry of phosphorylation is interpreted to indicate that the likely importance of phosphorylation is questionable. However, in this case, our approach was specifically designed to identify subcellular pools of phosphorylated proteins. The phototrapping data indicated RhoA was only phosphorylated when associated with Factin; thus, it is possible that the observed low stoichiometry is a reflection of a distinct cellular pool of total RhoA that is phosphoregulated. Further work is needed distinguish among all these possibilities. Two key phosphotyrosine binding sites, Y34 and Y66, were identified by peptide array-based SH2 overlay analysis, and these sites were confirmed as potential phosphorylation sites by mutagenesis. Using an unrelated global phosphoproteomic approach, RhoA Y34 was also recently detected in the cancer cell line H1703 (19) , further confirming this site as a likely tyrosine kinase substrate. We also screened several tyrosine kinases to determine which, if any, could target RhoA. From this screen, Src emerged as the best candidate, followed by Abl, which contains an F-actin binding domain (37) . Further Graph depicts the quantification of the RBD pull-downs as shown in C. Bars represent mean ± SEM (n = 3). (E) Induction of F-actin stress fiber formation by RhoA mutants. V5-tagged WT RhoA (wild), constitutive active RhoAQ63L (Q63L), phosphomimic forms of RhoAQ63L (34E, 66E, or 34,66E), or controls (34F, 66F, or 34,66F) were expressed in HeLa cells, followed by immunostaining with anti-V5 antibody and phalloidin and DAPI labeling. (Scale bars, 10 μm.) (F) Quantitative analysis of RhoA-induced F-actin stress fiber formation. The average fluorescence intensity of F-actin in each V5-RhoA mutant-expressing cell was measured. The fold induction of cellular stress fiber formation was calculated, normalized to RhoA. Bars represent mean ± SEM from three independent experiments (n ≥ 30). ***P < 0.001; **P < 0.01 in blue are mutants compared with RhoA. +++P < 0.0001; ++P < 0.01 in red are mutants compared with RhoAQ63L(Y34,66E).
work is required to identify conclusively the physiological tyrosine kinases that target RhoA; however, we note evidence in supplementary material of an article by Moritz et al. (19) that Gleevec, an Abl inhibitor, reduces the level of cellular RhoA Y34 phosphorylation. Previous reports have also shown that Src may, in fact, associate with RhoA and that Src phosphorylation can inhibit RhoA signaling, in part by phosphorylating and activating p190RhoGAP during integrin engagement (38) (39) (40) . Our data suggest there could be an additional, direct inhibitory effect of Src on a subfraction of RhoA as a result of phosphorylation of Y34 and Y66. Further work is required to demonstrate that tyrosine phosphorylation of endogenous RhoA is inhibitory.
Several RhoA structures in complex with effectors and modulators have been solved, and these structures indicate Y34 and Y66 are located in important positions for multiple RhoA protein-protein contacts. For example, the structure of RhoA-GTP in complex with the ROCK RBD revealed that Y66 is in the switch II region and is involved in both electrostatic and hydrophobic interactions with ROCK1 (41) . Also, Y66 is involved in the binding interaction with the HR1a domain of protein kinase C-related kinase 1, suggesting Y66 is critical for RhoA interactions with multiple types of effector binding domains (42) . Additionally, structural analysis of leukemia-associated RhoGEF in complex with RhoA revealed that Y34 is involved in the interaction (43) . Y34 is also critical for the activation of RhoA by the GEF AKAP-Lbc (44) . Indeed, the Y34 mutant of RhoA (RhoAY34E) abolished binding with AKAP-Lbc (Fig. S6) . These studies suggest phosphorylation on tyrosine 34 or 66 may yield distinct outcomes toward different classes of RhoA binding partners, yet the net outcome appears to be inhibition of RhoA-mediated signaling to the actin cytoskeleton. Consistent with a potential regulatory function for Y34, another inhibitory modification has been identified, the AMPlation of Y34, catalyzed by Fic domaincontaining proteins, which can also disrupt RhoA signaling (45) .
Interestingly, Y34 and Y66 are well conserved in Rho proteins, as well as in other small G-protein families (Fig. S7) . Consistent with this, we also identified H-Ras as a phosphotyrosine protein in the membrane-enriched PI cluster, and our SH2 overlay mapping identified the homologous tyrosines 32 and 64 as possible sites of phosphorylation-dependent binding (Figs. 3  and 4) . Additionally, Rac1, RalA, and Rab11a contain homologous tyrosine sites that have been reported to be phosphorylated (46, 19) . Furthermore, Y64 of Cdc42 (corresponding to the Y66 of RhoA) is also phosphorylated by Src after EGF stimulation, and this enhances the interaction between Cdc42 and Rho-GDP dissociation inhibitor (47) . Recently, Rac1 was shown to be phosphorylated on Y64 by Src and FAK in vitro (48) . Thus, the emerging data suggest that sites homologous to RhoA Y34 and Y66 in other small G proteins may function as previously undescribed phosphoregulatory sites targeted by tyrosine kinases to regulate cellular functions governed by different GTPase families.
In summary, this work describes a unique genetically encoded approach to discover phosphotyrosine proteins within the context of their spatial organization within the cell. This approach is based on the incorporation of the photoinducible cross-linking phenylalanine analog pBpa into the phosphotyrosine binding SH2 domain. Analysis of the identified proteins from each subcellular target confirms the overall approach successfully traps and enriches proteins from these defined compartments. Furthermore, this approach reveals unique targets for tyrosine kinases in different subcellular compartments that could be important for regulation. Additional analysis with SH2 domains with different binding specificities compared with Abl will likely expand the coverage of tyrosine kinase substrates within these subcellular sites.
Materials and Methods
Plasmids. A mammalian expression vector that coexpresses Eco-pBpaRS and B. stearothermophilus suppressor tRNA Tyr (a gift from Shigeyuki Yokoyama, University of Tokyo, Tokyo, Japan) was modified for TAP (14) . A strep-tag, followed by a calmodulin binding peptide (CBP), a V5 epitope, two tobacco etch virus protease cleavage sites, an HRV3C cleavage site, and a tandem protein A sequence, was inserted after a mammalian expression promoter. Unique RsrII and SbfI restriction sites were placed between the CBP and V5 epitope for subcloning SH2 domain coding sequences. The SH2 domain (aa 120-220, Uniprot P00519) derived from c-Abl was inserted, and the targeted sequences listed below were placed on the N terminus of SH2. Lifeact, MGVADLIKKFESISKEE (49); membrane (Mem), MLCCMRRTKQVEKNDEDQKI (50) (derived from neuromodulin); and mitochondria (Mito), MSVLTPLLLRGL-TGSARRLPVPRAKIHSL (51) (derived from cytochrome c oxidase subunit 8A) were used. The Lifeact was a gift from Michel Bagnat (Duke University). Other plasmids used in this study are detailed in SI Materials and Methods.
Photo-Cross Linking. Photo-cross linking was performed as described (14) . Briefly, on the day of transfection, a 1-L culture of FreeStyle 293 cells was grown in FreeStyle 293 medium (GIBCO) to a density of 1 × 10 6 cells/mL. Transfection was done following a modified polyethylenimine (PEI) protocol (52) . One milligram of the vector encoding TAP-tagged SH2 domain plus Eco-pBpaRS and suppressor tRNA Tyr was mixed with 2 mg of PEI in 50 mL of FreeStyle 293 medium and added to the cell culture after 10 min of incubation. pBpa (270 mg) was dissolved in 1.1 mL of 1 M NaOH and added to the cell culture following addition of 7.5 mL of 1 M Hepes buffer to the culture. After 3 d of incubation at 37°C, the cells were treated with 0.5 mM PV for 5 min, followed by exposure to UV light (365 nm) in a custom-built chamber. After 30 min of photo-cross linking in the chamber at 4°C, cells were collected by centrifugation and subjected to TAP purification. Detailed methods for TAP purification can be found in SI Materials and Methods.
MS. MS was carried out as previously described (14) . Briefly, all MS data were acquired on an LTQ-Orbitrap XL mass spectrometer (Thermo Scientific) operating in positive-ion mode with an electrospray voltage of 2.0 kV. The instrument was set to acquire a precursor MS scan in the Orbitrap XL mass spectrometer from m/z 40-2,000, with r = 60,000 at m/z 400 and a target automatic gain control setting of 1e6 ions. In a data-dependent mode of acquisition, tandem MS spectra of the five most abundant precursor ions were acquired in the Orbitrap XL mass spectrometer at r = 7,500 at m/z 400 with a target AGC setting of 2e5 ions. Maximum fill times were set to 1,000 ms for full MS scans and to 500 ms for tandem MS scans with minimum tandem MS triggering thresholds of 5,000 counts. For all experiments, fragmentation occurred in the LTQ linear ion trap, Finnigen LTQ (Thermo Electron Corporation), with a collision-induced dissociation energy setting of 35%, and a dynamic exclusion of 60 s was used for previously fragmented precursor ions. Details of qualitative identifications from raw liquid chromatography/tandem MS data can be found in SI Materials and Methods.
Hierarchical Clustering. Relative protein abundance in the sample prepared by TAP was quantified using spectral counting (53) . To normalize the relative protein abundance, the spectral counts were expressed as a percentage of the total spectra observed in the sample. Mean normalized spectral counts were obtained from multiple independent experiments (n ≥ 2 for each targeted SH2 domain). Hierarchical clustering was performed based on the uncentered Pearson correlation of the mean normalized spectral counts (54, 55) .
Peptide Array Synthesis and GST or GST-SH2amb Protein Overlay. Peptides (19mer) were synthesized as previously described (56) using Auto-Spot Robot ASP 222 (INTAVIS AG). The GST-SH2 domain was purified as previously described (57) . The peptide arrays were incubated with the GST-SH2 domain at a concentration of 100 nM in 5% (wt/vol) BSA for 2 h. After a wash with Trisbuffered saline/Tween-20, the GST fusion proteins were detected using HRPconjugated anti-GST antibody (BETHYL). Positive peptide spots were densitometrically quantified using ImageJ (National Institutes of Health). Phosphodependent binding strength was estimated by subtracting the intensity of phosphopeptide from nonphosphopeptide and then normalized to the control peptide. A peptide showing a binding strength over 20 was assessed as a phosphotyrosine-dependent SH2 binding peptide. Amber codon-modified SH2 proteins were purified by TAP purification and incubated with the peptide arrays derived from EGFR, followed by UV exposure, and bounded SH2 was detected with anti-V5 antibody.
Immunoprecipitation Experiments. Immunoprecipitation experiments using HEK 293T cells were performed as previously described (58) . Briefly, transfected cells were lysed and centrifuged, and the supernatant was incubated with V5 antibody-agarose (Sigma) or GFP trap-agarose (ChromoTek). After beads were washed with lysis buffer, sample buffer was added and subjected to immunoblotting. For endogenous RhoA precipitation, cells were lysed with radioimmunoprecipitation assay buffer, followed by sonication, and centrifuged, and the supernatant was incubated with agarose-conjugated anti-RhoA (26C4; Santa Cruz Biotechnology). Further details can be found in SI Materials and Methods.
Cell Preparation and Image Analysis. Transfected FreeStyle 293 cells were plated onto poly-D-lysine-coated coverslips, fixed, and stained with anti-V5 antibody (1:500; Invitrogen) or antiphosphotyrosine antibody (1:100, 4G10; Millipore). Images were taken on a Zeiss LSM 710 laser scanning confocal microscope with a 63×/1.4 N.A. oil-immersion objective or 20×/0.8 N.A. objective. Further details for quantification of phalloidin staining are provided in SI Materials and Methods.
2pFLIM Assay. Details of the 2pFLIM assay have been described previously (26) . mEGFP was excited with a Ti/sapphire laser (Mai Tai; Spectraphysics) tuned at a wavelength of 920 nm. Fluorescent images were collected using a 60×/0.9 N.A. objective (Olympus). For fluorescence lifetime imaging, a photoelectron multiplier tube with low transfer time spread (H7422-40p; Hamamatsu) was used. Fluorescence lifetime images were obtained using a time-correlated single-photon counting board (SPC-140; Becker and Hickl) controlled with custom software based on Scanimage software (open source software, Karel Svoboda, Janelia Farm, Ashburn, VA).
Statistical Tests. Statistical analysis was done using Excel 2007 (Microsoft Corporation). Unless otherwise noted, significance was evaluated using a two-tailed Student t test.
Tandem Affinity Purification. The cross-linked cell pellet was resuspended in 20 mL of tandem affinity purification (TAP) lysis buffer [50 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 7.5% (vol/vol) glycerol, 25 mM NaF, 0.5% Nonidet P-40, 1 mM Na3VO4, 1 mM DTT, 1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF), 2 μg/mL leupeptin/pepstatin], homogenized with Dounce homogenizer, and subjected to centrifugation (17,000 × g) for 30 min. The supernatant was further clarified by ultracentrifugation (136,000 × g) for 1 h. The supernatant was mixed with IgG-Sepharose beads (200-μL bed volume) and incubated for 3 h at 4°C. The beads were washed with TAP lysis buffer and 5 mL of tobacco etch virus (TEV) cleavage buffer [10 mM Tris (pH 7.5), 100 mM NaCl, 0.5 mM EDTA, 1% Triton × 100, 1 mM DTT, 1 mM AEBSF, 2 μg/mL leupeptin/pepstatin). Beads were then resuspended with 0.2 mL of TEV cleavage buffer and incubated with TEV protease (100 units) and HRV3C protease (20 units; Accelagen) for 3 h at room temperature and overnight at 4°C. The flow-through from the beads was mixed with calmodulin-Sepharose beads (400-μL bed volume) in 2× calmodulin binding peptide binding buffer [10 mM Tris (pH 7.5), 100 mM NaCl, 2 mM MgAc, 4 mM CaCl 2 , 2 mM imidazole, 0.1% Nonidet P-40, 1 mM DTT, 1 mM AEBSF, 2 μg/mL leupeptin/pepstatin) and incubated for 2 h. After being washed with calmodulin-rinsing buffer [50 mM ammonium bicarbonate (pH 8.0), 75 mM NaCl, 1 mM MgAc, 2 mM CaCl 2 , 1 mM imidazole, 1 mM AEBSF, 2 μg/mL leupeptin/pepstatin] and 50 mM ammonium bicarbonate, the column was incubated with calmodulin-elution buffer [50 mM ammonium bicarbonate (pH 8.0), 25 mM EGTA] containing 0.1% Rapigest for 10 min and eluted. Elution with calmodulinelution buffer without Rapigest was repeated three more times. The eluates were combined and concentrated with an Amicon Ultra-4 (Millipore) at a 30,000 molecular weight cutoff.
Qualitative Identifications from Raw Liquid Chromatography/Tandem MS Data. Raw liquid chromatography/tandem MS data files were processed in Mascot distiller (Matrix Science) and then submitted to Mascot database searches (Matrix Science) against a UniProt database (Homo sapiens taxonomy) containing both forward and reverse entries of each protein. Search tolerances of 10-ppm precursor and 0.02-Da product ions were applied to all searches. All data were searched using trypsin specificity with up to two missed cleavages. Carbamidomethylation (+57.0214 Da on C) was set as a fixed modification, whereas oxidation (+15.9949 Da on M) was considered a variable modification. Fig. S1 . Immunoblot (IB) analysis of c-Abl Src homology 2 (SH2) without p-benzoyl-L-phenylalanine under cross-linking conditions. High-molecular-weight species are not present (compare with Fig. 1D ), demonstrating the cross linking is specific to pBpa. PV, parvanadate. . Sequence alignment of RhoA and its related small G-protein families around switch regions. Black dots indicate the tyrosine sites in RhoA. Tyrosinephosphorylated residues (Y34 and Y66) revealed by this study are highlighted in red. Amino acids that are reported to be phosphorylated are highlighted by a red box (tyrosine) or circle (serine or threonine) for protein in the alignment. Alignment was constructed using Clustal Omega. The background color for amino acids corresponds to the conservation level (dark blue, well conserved; white, not conserved), as analyzed by Jalview version 2. UniProt accession numbers are as follows; RhoA P61586, RhoB P62745, RhoC P08134, Rac1 P63000, Cdc42 P40793, H-Ras P01112, Rap1A P62834, RalA P11233, Ran P62826, Arf6 P62330, Rab5A P20339, Rab11A P62491, and Rab4A P20338.
